AI responses may include mistakes. For financial advice, consult a professional. Learn more
As of April 2026, analysts generally hold a moderate buy rating for Gilead Sciences (GILD) , with many forecasting a potential upside from current prices. The company shows strength in its HIV portfolio, including Biktarvy, although some analysts express caution regarding declining revenue from other products.
AI responses may include mistakes. For financial advice, consult a professional. Learn more
As of April 2026, analysts generally hold a moderate buy rating for Gilead Sciences (GILD) , with many forecasting a potential upside from current prices. The company shows strength in its HIV portfolio, including Biktarvy, although some analysts express caution regarding declining revenue from other products.
